CEL-SCI CORPORATION Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings (Deprecated 2019-01-31)
CEL-SCI CORPORATION (CVM) reported Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings (Deprecated 2019-01-31) of -$5.56 million for the 3-month period ending 2018-12-31, per its 10-Q filed 2019-02-14.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings · last filed 2019-02-14
- CEL-SCI CORPORATION fair value, measured on recurring basis, gain (loss) included in earnings (deprecated 2019-01-31) for the quarter ending 2018-12-31 was -$5.56M, a 672.05% decline year-over-year.
- CEL-SCI CORPORATION fair value, measured on recurring basis, gain (loss) included in earnings (deprecated 2019-01-31) for the quarter ending 2018-09-30 was $8.84M.
- CEL-SCI CORPORATION fair value, measured on recurring basis, gain (loss) included in earnings (deprecated 2019-01-31) for the quarter ending 2018-06-30 was -$759.57K.
- CEL-SCI CORPORATION fair value, measured on recurring basis, gain (loss) included in earnings (deprecated 2019-01-31) for the quarter ending 2018-03-31 was -$1.16M, a 16121.57% decline year-over-year.
- CEL-SCI CORPORATION fair value, measured on recurring basis, gain (loss) included in earnings (deprecated 2019-01-31) for fiscal 2017 was -$7.93M.
- CEL-SCI CORPORATION fair value, measured on recurring basis, gain (loss) included in earnings (deprecated 2019-01-31) for fiscal 2016 was -$9.76M.
- CEL-SCI CORPORATION fair value, measured on recurring basis, gain (loss) included in earnings (deprecated 2019-01-31) for fiscal 2015 was -$1.99M, a 333.89% decline from fiscal 2014.
- CEL-SCI CORPORATION fair value, measured on recurring basis, gain (loss) included in earnings (deprecated 2019-01-31) for fiscal 2014 was $850.02K.
| Period end | Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings (Deprecated 2019-01-31) 3 month | Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings (Deprecated 2019-01-31) 6 month | Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings (Deprecated 2019-01-31) 9 month | Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings (Deprecated 2019-01-31) 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$5.56M 10-Q · filed 2019-02-14 | $3.28M derived: sum of 2 quarters · filed 2019-02-14 | $2.52M derived: sum of 3 quarters · filed 2019-02-14 | $1.36M derived: sum of 4 quarters · filed 2019-02-14 |
| 2018-09-30 | $8.84M derived: 10-Q 12 month − 10-Q 9 month · filed 2019-02-14 | $8.08M derived: sum of 2 quarters · filed 2019-02-14 | $6.92M derived: sum of 3 quarters · filed 2019-02-14 | $7.89M 10-Q · filed 2019-02-14 |
| 2018-06-30 | -$759.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-14 | -$1.92M derived: sum of 2 quarters · filed 2018-08-14 | -$944.23K 10-Q · filed 2018-08-14 | -$2.24M derived: sum of 4 quarters · filed 2018-12-19 |
| 2018-03-31 | -$1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-15 | -$184.66K 10-Q · filed 2018-05-15 | -$1.48M derived: sum of 3 quarters · filed 2018-12-19 | -$1.81M derived: sum of 4 quarters · filed 2018-12-19 |
| 2017-12-31 | $971.30K 10-Q · filed 2018-02-12 | -$324.04K derived: sum of 2 quarters · filed 2018-12-19 | -$657.55K derived: sum of 3 quarters · filed 2018-12-19 | -$650.34K derived: sum of 4 quarters · filed 2018-12-19 |
| 2017-09-30 | -$1.30M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-12-19 | -$1.63M derived: sum of 2 quarters · filed 2018-12-19 | -$1.62M derived: sum of 3 quarters · filed 2018-12-19 | -$7.93M 10-K · filed 2018-12-19 |
| 2017-06-30 | -$333.51K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-12-11 | -$326.30K derived: sum of 2 quarters · filed 2017-12-11 | -$6.63M 10-Q/A · filed 2017-12-11 | -$11.79M derived: sum of 4 quarters · filed 2017-12-29 |
| 2017-03-31 | $7.21K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-12-11 | -$6.30M 10-Q/A · filed 2017-12-11 | -$11.46M derived: sum of 3 quarters · filed 2017-12-29 | -$13.68M derived: sum of 4 quarters · filed 2017-12-29 |
| 2016-12-31 | -$6.31M 10-Q/A · filed 2017-12-11 | -$11.46M derived: sum of 2 quarters · filed 2017-12-29 | -$13.69M derived: sum of 3 quarters · filed 2017-12-29 | -$10.77M derived: sum of 4 quarters · filed 2017-12-29 |
| 2016-09-30 | -$5.16M derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-29 | -$7.38M derived: sum of 2 quarters · filed 2017-12-29 | -$4.46M derived: sum of 3 quarters · filed 2017-12-29 | -$9.76M 10-K · filed 2017-12-29 |
| 2016-06-30 | -$2.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | $691.70K derived: sum of 2 quarters · filed 2016-08-09 | -$4.61M 10-Q · filed 2016-08-09 | -$5.26M derived: sum of 4 quarters · filed 2017-12-11 |
| 2016-03-31 | $2.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-10 | -$2.38M 10-Q · filed 2016-05-10 | -$3.03M derived: sum of 3 quarters · filed 2017-12-11 | -$4.35M derived: sum of 4 quarters · filed 2017-12-11 |
| 2015-12-31 | -$5.30M 10-Q · filed 2016-02-09 | -$5.95M derived: sum of 2 quarters · filed 2017-12-11 | -$7.27M derived: sum of 3 quarters · filed 2017-12-11 | -$7.07M derived: sum of 4 quarters · filed 2017-12-11 |
| 2015-09-30 | -$651.62K derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-12-11 | -$1.97M derived: sum of 2 quarters · filed 2017-12-11 | -$1.78M derived: sum of 3 quarters · filed 2017-12-11 | -$1.99M 10-K/A · filed 2017-12-11 |
| 2015-06-30 | -$1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-07 | -$1.12M derived: sum of 2 quarters · filed 2015-08-07 | -$1.34M 10-Q · filed 2015-08-07 | -$1.69M derived: sum of 4 quarters · filed 2015-12-11 |
| 2015-03-31 | $193.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-08 | -$19.05K 10-Q · filed 2015-05-08 | -$376.60K derived: sum of 3 quarters · filed 2015-12-11 | -$925.89K derived: sum of 4 quarters · filed 2015-12-11 |
| 2014-12-31 | -$212.59K 10-Q · filed 2015-02-06 | -$570.14K derived: sum of 2 quarters · filed 2015-12-11 | -$1.12M derived: sum of 3 quarters · filed 2015-12-11 | $2.25M derived: sum of 4 quarters · filed 2015-12-11 |
| 2014-09-30 | -$357.55K derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11 | -$906.85K derived: sum of 2 quarters · filed 2015-12-11 | $2.46M derived: sum of 3 quarters · filed 2015-12-11 | $850.02K 10-K · filed 2015-12-11 |
| 2014-06-30 | -$549.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-08-08 | $2.82M derived: sum of 2 quarters · filed 2014-08-08 | $1.21M 10-Q · filed 2014-08-08 | -$2.18M derived: sum of 4 quarters · filed 2014-12-23 |
| 2014-03-31 | $3.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-12 | $1.76M 10-Q · filed 2014-05-12 | -$1.63M derived: sum of 3 quarters · filed 2014-12-23 | -$2.71M derived: sum of 4 quarters · filed 2014-12-23 |
| 2013-12-31 | -$1.61M 10-Q · filed 2014-02-10 | -$5.00M derived: sum of 2 quarters · filed 2014-12-23 | -$6.08M derived: sum of 3 quarters · filed 2014-12-23 | -$9.61M derived: sum of 4 quarters · filed 2014-12-23 |
| 2013-09-30 | -$3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2014-12-23 | -$4.47M derived: sum of 2 quarters · filed 2014-12-23 | -$8.00M derived: sum of 3 quarters · filed 2014-12-23 | -$10.75M 10-K · filed 2014-12-23 |
| 2013-06-30 | -$1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-09 | -$4.62M derived: sum of 2 quarters · filed 2013-08-09 | -$7.36M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | -$3.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-05-10 | -$6.28M 10-Q · filed 2013-05-10 | ||
| 2012-12-31 | -$2.75M 10-Q · filed 2013-02-08 | |||
| 2012-09-30 | -$1.91M 10-K · filed 2013-12-27 | |||
| 2011-09-30 | -$4.43M 10-K · filed 2012-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |